Advances in Research of Drugs for Treating Respiratory Syncytial Virus / 中国实验方剂学杂志

ABSTRACT

Respiratory syncytial virus (RSV) is an RNA virus, which belongs to the paramyxoviridae family, and is transmitted by air droplets and close contact and the main pathogen causing acute lower respiratory tract infection in infants, the elderly and immunocompromised individuals.Although there have been studies on the prevention and treatment of RSV drugs and RSV infection in patients, many medical demands have not been met.And there is no specific antiviral therapy.The only two drugs approved to be applied in RSV prevention and treatment are perizol and ribavirin.However, the former must be used prophylactically, and primarily in high-risk children, while the latter is less effective, and some children even suffer from airway spasm.Therefore, it is urgent to propose new methods for prevention and treatment of RSV.In recent years, traditional Chinese medicine(TCM) has shown a good anti-RSV effect, with a fewer side effects, less resistance to drugs and broad-spectrum antiviral advantage.There are also newly developed biological and chemical anti-RSV drugs.Some new drugs have shown a good efficacy, with an extended half-life and reduced costs, such as fusion inhibitors, monoclonal antibodies.This paper reviews the research progress of anti-RSV drugs in the aspects of TCM, biological drug and chemical drugs, laying a foundation for the development of new anti-RSV drugs and the formulation of new therapeutic strategies.